Pharmacokinetics Study of Larotinib in Subjects With Impaired Hepatic Function

Inclusion Criteria: * healthy subjects with normal hepatic function (cohorts A and C) : * 1\. Sign the informed consent form before the trial； * 2\. subjects and must be 18 to 70 years of age inclusive, Male or female. body weight \>50 kg (male) or ≥45 kg (female) at screening. (BMI) : 18-30 kg/m\^2, (including critical value) \[BMI= weight (kg)/height\^2 (m\^2)\] (BMI matching ±15% with liver dysfunction cohort); * 3.Must be in good health as determined by past medical history, physical examination, vital signs, ECG, and laboratory tests at Screening； * 4.Subjects (including partners) have no pregnancy plan within 6 months after the last dose of study drug and voluntarily take effective contraceptive measures. * Subjects with mild/ Moderate hepatic Impairment (cohorts B and D) : * 1\. Sign the informed consent form before the trial. * 2\. subjects and must be 18 to 70 years of age inclusive, Male or female. body weight \>50 kg (male) or ≥45 kg (female) at screening. (BMI) : 18-30 kg/m\^2； * 3\. Must satisfy the criteria for hepatic Impairment as evidenced by a Child-Pugh class of A or B at Screening:Class A; Mild; Child-Pugh score 5-6；Class B; Moderate; Child-Pugh score 7-9 * 4\. The liver function status of the subjects was determined to be stable between 1 month before taking the experimental drug and the end of the study, with no significant change. * 5\. Subjects (including partners) have no pregnancy plan within 6 months after the last dose of study drug and voluntaril…